Guardant Health’s newly FDA-approved blood test, Shield, offers a non-invasive screening option for colorectal cancer. This liquid biopsy test detects tumor DNA fragments in the blood, providing an alternative to traditional colonoscopies. The approval is expected to boost screening rates and facilitate early detection, especially for those reluctant to undergo more invasive procedures. The Shield test’s development highlights advances in cancer diagnostics and the potential for broader access to early cancer detection.
F.D.A. Approves Blood Test for Colon Cancer Detection (The New York Times)
0